Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 10/20 | 0.45 |
| ▸ | NMT2 | O60551 | 9/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678508 | 0.91 | NMT1 (0.49) | NMT1NMT2FOLH1TLR2 | |
| SCHEMBL30887360 | 0.90 | NMT1 (0.45) | NMT1NMT2FOLH1GNPATTLR2 | |
| SCHEMBL30887359 | 0.90 | NMT1 (0.45) | NMT1NMT2FOLH1GNPATTLR2 | |
| SCHEMBL29367996 | 0.89 | NMT1 (0.47) | NMT1NMT2FOLH1GNPATTLR2 | |
| SCHEMBL30445612 | 0.89 | NMT1 (0.49) | NMT1NMT2FOLH1TLR2 | |
| SCHEMBL29915407 | 0.89 | FOLH1 (0.49) | NMT1NMT2FOLH1GNPATTLR2 | |
| SCHEMBL29474449 | 0.88 | FOLH1 (0.47) | FOLH1GNPAT | |
| SCHEMBL29757022 | 0.88 | TERT (0.47) | NMT1NMT2FOLH1GNPAT | |
| SCHEMBL30397555 | 0.87 | NMT1 (0.53) | NMT1NMT2TLR2 | |
| SCHEMBL30398397 | 0.87 | NMT1 (0.53) | NMT1NMT2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | UNIVERSITY OF IDAHO | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | ASS1, GFER, ASIC1 | NMT1 3435/4885NMT2 3513/4885FOLH1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.